Nvwm, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Nvwm, LLC

$382 Million
Q3 2024

A detailed history of Nvwm, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Nvwm, LLC holds 988 shares of REGN stock, worth $747,728. This represents 0.27% of its overall portfolio holdings.

Number of Shares

988

Previous 974 1.44%

Holding current value

$747,728

Previous $1.02 Million 1.47%

% of portfolio

0.27%

Previous 0.28%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	BUY	$1024.09 - $1201.76 $14,337 - $16,824	14 Added 1.44%	988 $1.04 Million
Q2 2024 Aug 13, 2024	SELL	$883.2 - $1071.19 $4,416 - $5,355	-5 Reduced 0.51%	974 $1.02 Million
Q1 2024 May 06, 2024	BUY	$902.69 - $993.35 $75,825 - $83,441	84 Added 9.39%	979 $942,000
Q4 2023 Feb 07, 2024	BUY	$775.18 - $881.7 $693,786 - $789,121	895 New	895 $786,000
Q4 2021 Feb 08, 2022	BUY	$543.48 - $670.97 $3,260 - $4,025	6 Added 85.71%	13 $8,000
Q3 2021 Nov 03, 2021	BUY	$574.03 - $680.96 $4,018 - $4,766	7 New	7 $4,000
Q4 2020 Feb 09, 2021	SELL	$478.3 - $607.98 $508,911 - $646,890	-1,064 Closed	0 $0
Q3 2020 Dec 10, 2020	BUY	$544.75 - $658.21 $23,424 - $28,303	43 Added 4.21%	1,064 $596,000
Q2 2020 Aug 11, 2020	BUY	$493.32 - $643.92 $986 - $1,287	2 Added 0.2%	1,021 $637,000
Q1 2020 May 08, 2020	BUY	$336.18 - $494.43 $342,567 - $503,824	1,019 New	1,019 $498,000
Q2 2019 Aug 07, 2019	SELL	$299.6 - $414.82 $315,179 - $436,390	-1,052 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$372.08 - $439.57 $391,428 - $462,427	1,052 New	1,052 $432,000

Others Institutions Holding REGN

# of Institutions

1,529

Shares Held

84.1M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $81.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nvwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nvwm, LLC with notifications on news.

Account